Events
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
-
-
In one cancer therapy, two halves are safer than a whole
Splitting one type of cancer drug in half and delivering the pieces separately to cancer…
New Surgical Approach for Women at Risk of Ovarian Cancer
A new two-stage surgical approach for cancer prevention is highly acceptable among premenopausal women at…
ESMO issues first recommendations on using next-generation sequencing for advanced cancers
Recommendations on the use of next-generation sequencing (NGS) for patients with metastatic cancers are being…
Should ovarian and breast cancer patients be tested for the BRCA gene?
COSA 2016: Oncology professionals at the COSA ANZBCTG Meeting this afternoon discussed emerging evidence that showed the potential benefits of…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.